|
Author(s)
Ethan Basch, MD, MPhil
Catherine Ulbricht, PharmD
E-P Barrette, MD
Samuel Basch, MD
Steve Bent, MD
Heather Boon, BScPhm, PhD
Cynthia Dacey, PharmD
Edzard Ernst, MD, PhD
Mamta Vora, PharmD
Peter Wolsko, MD
Paul Hammerness, MD
|
Abstract:
Evening primrose oil (EPO) contains an omega-6 essential fatty acid, gamma-linolenic acid (GLA), which is felt to be the active ingredient. EPO has been studied in a wide variety of disorders, particularly those affected by metabolic products of essential fatty acids. However, high-quality evidence for its use in most indications is still lacking. GLA has been officially licensed for the treatment of non-cyclical breast pain (mastalgia) in England, and for the treatment of eczema in numerous countries, including England, Germany, Ireland, South Africa and Italy
This article is accessible only to IntJNM
Members |
|
|
|
